Wyszuk. zaawans.

Tom 15, Nr 4 (2019)
Wytyczne / stanowisko ekspertów
Opublikowany online: 2020-01-28

dostęp otwarty

Pokaż PDF Pobierz plik PDF
Wyświetlenia strony 4360
Wyświetlenia/pobrania artykułu 9738
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Leczenie i postępowanie objawowe w stwardnieniu rozsianym Rekomendacje Sekcji SM i Neuroimmunologii Polskiego Towarzystwa Neurologicznego

Beata Zakrzewska-Pniewska1, Monika Adamczyk-Sowa2, Waldemar Brola3, Alicja Kalinowska4, Alina Kułakowska5, Jacek Losy6, Dagmara Mirowska-Guzel7, Andrzej Potemkowski8, Konrad Rejdak9, Iwona Sarzyńska-Długosz10, Małgorzata Siger11, Jacek Zaborski12, Halina Bartosik-Psujek13
DOI: 10.5603/PPN.2019.0033
Pol. Przegl. Neurol 2019;15(4):191-217.

Streszczenie

Zespół ekspertów Polskiego Towarzystwa Neurologicznego opracował zasady postępowania w leczeniu poszczególnych objawów występujących u pacjentów ze stwardnieniem rozsianym. Rekomendacje opracowano na podstawie wyników najnowszych badań klinicznych, zaleceń zagranicznych towarzystw naukowych oraz własnego doświadczenia klinicznego autorów. Omówiono postępowanie w spastyczności, ataksji i drżeniu, zespole zmęczenia, w przypadku zaburzeń zwieraczy dróg moczowych i przewodu pokarmowego, zaburzeń seksualnych oraz w zespołach bólowych występujących typowo w stwardnieniu rozsianym. Przedstawiono również zasady postępowania w przypadku zaburzeń psychicznych i zaburzeń funkcji poznawczych. W dokumencie podsumowano możliwości terapii objawowej w stwardnieniu rozsianym w warunkach polskich.

Słowa kluczowe: rekomendacjeleczenie objawowestwardnienie rozsiane

Artykuł dostępny w formacie PDF

Pokaż PDF Pobierz plik PDF

Referencje

  1. Lance JW. Spasticity: disordered motor control. In: Feldman RG, Young RR, Koella WP. ed. Symposium Synopsis. Year Book Medical Publishers, Chicago 1980: 485–494.
  2. Henze T, Feneberg W, Flachenecker P, et al. [What is new in symptomatic MS treatment: part 2-gait disorder and spasticity] [Article in German]. Nervenarzt. 2017; 88(12): 1428–1434.
    CrossRefPubMed
  3. Rizzo MA, Hadjimichael OC, Preiningerova J, et al. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004; 10(5): 589–595.
    CrossRefPubMed
  4. Smith CR, LaRocca NG, Giesser BS, et al. High-dose oral baclofen: experience in patients with multiple sclerosis. Neurology. 1991; 41(11): 1829–1831.
    CrossRefPubMed
  5. Ward AB. Long-term modification of spasticity. J Rehabil Med. 2003(41 Suppl): 60–65.
    CrossRefPubMed
  6. Platz T, Eickhof C, Nuyens G, et al. Clinical scales for the assessment of spasticity, associated phenomena, and function: a systematic review of the literature. Disabil Rehabil. 2005; 27(1–2): 7–18.
    CrossRefPubMed
  7. Haugh AB, Pandyan AD, Johnson GR. A systematic review of the Tardieu Scale for the measurement of spasticity. Disabil Rehabil. 2006; 28(15): 899–907.
    CrossRefPubMed
  8. Priebe MM, Sherwood AM, Thornby JI, et al. Clinical assessment of spasticity in spinal cord injury: a multidimensional problem. Arch Phys Med Rehabil. 1996; 77(7): 713–716.
    CrossRefPubMed
  9. Hobart JC, Riazi A, Thompson AJ, et al. Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). Brain. 2006; 129(Pt 1): 224–234.
    CrossRefPubMed
  10. Ward A, Wissel J, Borg J, et al. Functional goal achievement in post-stroke spasticity patients: The BOTOX® Economic Spasticity Trial (BEST). J Rehabil Med. 2014; 46(6): 504–513.
    CrossRefPubMed
  11. Royal College of Physicians, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Association of Chartered Physiotherapists Interested in Neurology. Spasticity in adults: management using botulinum toxin. National guidelines RCP, London 2009.
  12. Henze T, Rieckmann P, Toyka KV, et al. Multiple Sclerosis Therapy Consensus Group of the German Multiple Sclerosis Society. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol. 2006; 56(2): 78–105.
    CrossRefPubMed
  13. Gold R, Oreja-Guevara C. Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines. Expert Rev Neurother. 2013; 13(12 Suppl): 55–59.
    CrossRefPubMed
  14. Toosy A, Ciccarelli O, Thompson A. Symptomatic treatment and management of multiple sclerosis. Handb Clin Neurol. 2014; 122: 513–562.
    CrossRefPubMed
  15. Otero-Romero S, Sastre-Garriga J, Comi G, et al. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. Mult Scler. 2016; 22(11): 1386–1396.
    CrossRefPubMed
  16. Thompson AJ, Toosy AT, Ciccarelli O. Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. Lancet Neurol. 2010; 9(12): 1182–1199.
    CrossRefPubMed
  17. MS Council for Clinical Practical Guidelines. Spasticity management in multiple sclerosis. J Spinal Cord Med. 2005; 28: 167–200.
  18. Toosy A, Ciccarelli O, Thompson A. Symptomatic treatment and management of multiple sclerosis. In: Goodin DD, Ciccarelli O, Thompson A. ed. Handbook of clinical neurology. Vol. 22 (3rd series). Multiple sclerosis and related disorders. Elsevier, Philadelpia 2014: 518–520.
  19. The morbidity of multiple sclerosis. Q J Med. 1992; 83(1): 325–337.
    CrossRef
  20. Mills RJ, Yap L, Young CA. Treatment for ataxia in multiple sclerosis. Cochrane Database Syst Rev. 2007(1): CD005029.
    CrossRefPubMed
  21. Ghez C, Thach WT. The cerebellum. Principles of neural science. 4th edition. McGraw Hill, New York 2000.
  22. Koch M, Mostert J, Heersema D, et al. Tremor in multiple sclerosis. J Neurol. 2007; 254(2): 133–145.
    CrossRefPubMed
  23. Alusi SH, Worthington J, Glickman S, et al. A study of tremor in multiple sclerosis. Brain. 2001; 124(Pt 4): 720–730.
    CrossRefPubMed
  24. Pittock SJ, McClelland RL, Mayr WT, et al. Prevalence of tremor in multiple sclerosis and associated disability in the Olmsted County population. Mov Disord. 2004; 19(12): 1482–1485.
    CrossRefPubMed
  25. Wilkins A, Kemp K, Redondo J, et al. Oxidative injury in multiple sclerosis cerebellar grey matter. Brain Res. 2016; 1642: 452–460.
    CrossRefPubMed
  26. Trouillas P, Takayanagi T, Hallett M, et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci. 1997; 145(2): 205–211.
    CrossRefPubMed
  27. Henze T, Feneberg W, Flachenecker P, et al. [What is new in symptomatic MS treatment: part 1-introduction and methodical approach, ataxia and tremor] [Article in German]. Nervenarzt. 2017; 88(12): 1421–1427.
    CrossRefPubMed
  28. Schapiro RT. Managing the symptoms of multiple sclerosis. 4th edition. Demos, New York 204: 46–51.
  29. Koller WC. Pharmacologic trials in the treatment of cerebellar tremor. Arch Neurol. 1984; 41(3): 280–281.
    CrossRefPubMed
  30. Sechi GP, Zuddas M, Piredda M, et al. Treatment of cerebellar tremors with carbamazepine: a controlled trial with long-term follow-up. Neurology. 1989; 39(8): 1113–1115.
    CrossRefPubMed
  31. Naderi F, Javadi SA, Motamedi M, et al. The efficacy of primidone in reducing severe cerebellar tremors in patients with multiple sclerosis. Clin Neuropharmacol. 2012; 35(5): 224–226.
    CrossRefPubMed
  32. Schroeder A, Linker RA, Lukas C, et al. Successful treatment of cerebellar ataxia and tremor in multiple sclerosis with topiramate: a case report. Clin Neuropharmacol. 2010; 33(6): 317–318.
    CrossRefPubMed
  33. Sechi G, Agnetti V, Sulas FMI, et al. Effects of topiramate in patients with cerebellar tremor. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27(6): 1023–1027.
    CrossRefPubMed
  34. Trelles L, Trelles JO, Castro C, et al. Successful treatment of two cases of intention tremor with clonazepam. Ann Neurol. 1984; 16(5): 621.
    CrossRefPubMed
  35. Bittar RG, Hyam J, Nandi D, et al. Thalamotomy versus thalamic stimulation for multiple sclerosis tremor. J Clin Neurosci. 2005; 12(6): 638–642.
    CrossRefPubMed
  36. Schuurman PR, Bosch DA, Merkus MP, et al. Long-term follow-up of thalamic stimulation versus thalamotomy for tremor suppression. Mov Disord. 2008; 23(8): 1146–1153.
    CrossRefPubMed
  37. Timmermann L, Deuschl G, Fogel W, et al. Deep Brain Stimulation Association. [Deep brain stimulation for tremor in multiple sclerosis: consensus recommendations of the German Deep Brain Stimulation Association] [Article in German]. Nervenarzt. 2009; 80(6): 673–677.
    CrossRefPubMed
  38. Giovanni G. Multiple sclerosis related fatigue. J Neurol Neurosurg Psychiatry. 2006; 77: 2–5.
  39. Braley TJ, Chervin RD. Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment. Sleep. 2010; 33(8): 1061–1067.
    CrossRefPubMed
  40. Dittner AJ, Wessely SC, Brown RG. The assessment of fatigue: a practical guide for clinicians and researchers. J Psychosom Res. 2004; 56(2): 157–170.
    CrossRefPubMed
  41. Brola W, Ziomek M, Czernicki J. Zmęczenie w przewlekłych chorobach neurologicznych. Neurol Neurochir Pol. 2007; 41: 340–349.
  42. Janardhan V, Bakshi R. Quality of life in patients with multiple sclerosis: the impact of fatigue and depression. J Neurol Sci. 2002; 205(1): 51–58.
    CrossRefPubMed
  43. Merkelbach S, Sittinger H, Koenig J. Is there a differential impact of fatigue and physical disability on quality of life in multiple sclerosis? J Nerv Ment Dis. 2002; 190(6): 388–393.
    CrossRefPubMed
  44. Schapiro RT, Schapiro RT, Schapiro RT. Medications used in the treatment of multiple sclerosis. Phys Med Rehabil Clin N Am. 1999; 10(2): 437–46, ix.
    PubMed
  45. Iriarte J, Katsamakis G, de Castro P. The Fatigue Descriptive Scale (FDS): a useful tool to evaluate fatigue in multiple sclerosis. Mult Scler. 1999; 5(1): 10–16.
    CrossRefPubMed
  46. Veauthier C, Hasselmann H, Gold SM, et al. The Berlin Treatment Algorithm: recommendations for tailored innovative therapeutic strategies for multiple sclerosis-related fatigue. EPMA J. 2016; 7: 25.
    CrossRefPubMed
  47. Achiron A, Givon U, Magalashvili D, et al. Effect of alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Mult Scler. 2015; 21(6): 767–775.
    CrossRefPubMed
  48. Allart E, Benoit A, Blanchard-Dauphin A, et al. Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life. J Neurol. 2015; 262(8): 1936–1945.
    CrossRefPubMed
  49. Beckerman H, Blikman LJm, Heine M, et al. TREFAMS-ACE study group. The effectiveness of aerobic training, cognitive behavioural therapy, and energy conservation management in treating MS-related fatigue: the design of the TREFAMS-ACE programme. Trials. 2013; 14: 250.
    CrossRefPubMed
  50. Betts CD. Bladder and sexual dysfunction in multiple sclerosis. In: Fowler CJ. ed. Neurology of bladder, bowel, and sexual dysfunction: blue books of practical neurology. Butterworth-Heinemann, Boston 1999: 289–308.
  51. Goodwin RJ, Fowler CG. Bladder, bowel and sexual dysfunction: recent advances. In: Thompson AJ, Polman CH, Hohlfeld R. ed. Multiple sclerosis: clinical challenges and controversies. Martin Dunitz, London 1997: 265–281.
  52. Kalsi V, Fowler CJ. Therapy Insight: bladder dysfunction associated with multiple sclerosis. Nat Clin Pract Urol. 2005; 2(10): 492–501.
    CrossRefPubMed
  53. Araki I, Matsui M, Ozawa K, et al. Relationship of bladder dysfunction to lesion site in multiple sclerosis. J Urol. 2003; 169(4): 1384–1387.
    CrossRefPubMed
  54. Birder L, de Groat W, Mills I, et al. Neural control of the lower urinary tract: peripheral and spinal mechanisms. Neurourol Urodyn. 2010; 29(1): 128–139.
    CrossRefPubMed
  55. Pannek J, Blok B, Castro-Diaz D, et al. ed. Guidelines on neurogenic lower tract dysfunction. European Association of Urology 2013. https://uroweb.org/wp-content/uploads/20_Neurogenic-LUTD_LR.pdf (22.11.2019).
  56. Markowitz C. Symptomatic therapy of multiple sclerosis. Continuum (Minneap Minn). 2010; 16(5 Multiple Sclerosis): 90–104.
    CrossRefPubMed
  57. Bigi S, Yeh E. Symptomatic treatment in multiple sclerosis. US Neurology. 2013; 09(01): 35.
    CrossRef
  58. Fowler CJ, van Kerrebroeck PE, Nordenbo A, et al. Treatment of lower urinary tract dysfunction in patients with multiple sclerosis. Committee of the European Study Group of SUDIMS (Sexual and Urological Disorders in Multiple Sclerosis). J Neurol Neurosurg Psychiatry. 1992; 55(11): 986–989.
    CrossRefPubMed
  59. Kaplan SA, Goldfischer ER, Steers WD, et al. Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes. Aging Male. 2010; 13(2): 100–107.
    CrossRefPubMed
  60. Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract. 2008; 62(11): 1792–1800.
    CrossRefPubMed
  61. Wöllner J, Pannek J. Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinal cord injury. Spinal Cord. 2016; 54(1): 78–82.
    CrossRefPubMed
  62. Kuo HC. Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction. J Urol. 2003; 170(5): 1908–1912.
    CrossRefPubMed
  63. Jamison J, Maguire S, McCann J. Catheter policies for management of long term voiding problems in adults with neurogenic bladder disorders. Cochrane Database Syst Rev. 2013(11): CD004375.
    CrossRefPubMed
  64. Khan S, Game X, Kalsi V, et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol. 2007; 62(5): 452–457.
    CrossRefPubMed
  65. El Yazami Adli O, Crocos J. Botulinum neurotoxin — a treatment of lower urinary tract symptoms in multiple sclerosis. Can Urol Assoc J. 2014; 8(1–2): E61–E67.
    CrossRefPubMed
  66. Gabay B, Maucort-Boulch D, Ruffion A, et al. [Long-term outcomes of intradetrusor botulinum toxin A in multiple sclerosis patients] [Article in French]. Prog Urol. 2019; 29(3): 156–165.
    CrossRefPubMed
  67. Hinds JP, Eidelman BH, Wald A. Prevalence of bowel dysfunction in multiple sclerosis. A population survey. Gastroenterology. 1990; 98(6): 1538–1542.
    CrossRefPubMed
  68. Munteis E, Andreu M, Téllez MJ, et al. Anorectal dysfunction in multiple sclerosis. Mult Scler. 2006; 12(2): 215–218.
    CrossRefPubMed
  69. Preziosi G, Gordon-Dixon A, Emmanuel A. Neurogenic bowel dysfunction in patients with multiple sclerosis: prevalence, impact, and management strategies. Degener Neurol Neuromuscul Dis. 2018; 8: 79–90.
    CrossRefPubMed
  70. Preziosi G, Raptis DA, Raeburn A, et al. Gut dysfunction in patients with multiple sclerosis and the role of spinal cord involvement in the disease. Eur J Gastroenterol Hepatol. 2013; 25(9): 1044–1050.
    CrossRefPubMed
  71. Thiruppathy K, Preziosi G. Multiple sclerosis related bowel dysfunction: pathophysiology, clinical manifestation and management. J Neurol Neurophysiol. 2014; 05(06).
    CrossRef
  72. Wiesel PH, Norton C, Glickman S, et al. Pathophysiology and management of bowel dysfunction in multiple sclerosis. Eur J Gastroenterol Hepatol. 2001; 13(4): 441–448.
    CrossRefPubMed
  73. Preziosi G, Raptis DA, Storrie J, et al. Bowel biofeedback treatment in patients with multiple sclerosis and bowel symptoms. Dis Colon Rectum. 2011; 54(9): 1114–1121.
    CrossRefPubMed
  74. Betts CD, Jones SJ, Fowler CG, et al. Erectile dysfunction in multiple sclerosis. Associated neurological and neurophysiological deficits, and treatment of the condition. Brain. 1994; 117 ( Pt 6): 1303–1310.
    CrossRefPubMed
  75. Fletcher SG, Castro-Borrero W, Remington G, et al. Sexual dysfunction in patients with multiple sclerosis: a multidisciplinary approach to evaluation and management. Nat Clin Pract Urol. 2009; 6(2): 96–107.
    CrossRefPubMed
  76. Zorzon M, Zivadinov R, Bosco A, et al. Sexual dysfunction in multiple sclerosis: a case-control study. I. Frequency and comparison of groups. Mult Scler. 1999; 5(6): 418–427.
    CrossRefPubMed
  77. Fraser C, Mahoney J, McGurl J. Correlates of sexual dysfunction in men and women with multiple sclerosis. J Neurosci Nurs. 2008; 40(5): 312–317.
    CrossRefPubMed
  78. Kessler TM, Fowler CJ, Panicker JN. Sexual dysfunction in multiple sclerosis. Expert Rev Neurother. 2009; 9(3): 341–350.
    CrossRefPubMed
  79. O’Connor AB, Schwid SR, Herrmann DN, et al. associated with multiple sclerosis: systematic review and proposed classification. Pain. 2008; 137: 96–111.
  80. Osterberg A, Boivie J, Thuomas KA. Central pain in multiple sclerosis — prevalence and clinical characteristics. Eur J Pain. 2005; 9(5): 531–542.
    CrossRefPubMed
  81. Truini A, Galeotti F, Cruccu G. Treating pain in multiple sclerosis. Expert Opin Pharmacother. 2011; 12(15): 2355–2368.
    CrossRefPubMed
  82. Ehde DM, Osborne TL, Hanley MA, et al. Chronic pain in persons with multiple sclerosis. Phys Med Rehabil Clin N Am. 2005; 16(2): 503–512.
    CrossRefPubMed
  83. Malec-Milewska M. Ból u chorych na stwardnienie rozsiane. Med Paliat Prakt. 2014; 8: 29–40.
  84. Cruccu G, Biasiotta A, Di Rezze S, et al. Trigeminal neuralgia and pain related to multiple sclerosis. Pain. 2009; 143(3): 186–191.
    CrossRefPubMed
  85. Finnerup NB, Gottrup H, Jensen TS. Anticonvulsants in central pain. Expert Opin Pharmacother. 2002; 3(10): 1411–1420.
    CrossRefPubMed
  86. Solaro C, Uccelli MM. Management of pain in multiple sclerosis: a pharmacological approach. Nat Rev Neurol. 2011; 7(9): 519–527.
    CrossRefPubMed
  87. Al-Araji AH, Oger J. Reappraisal of Lhermitte's sign in multiple sclerosis. Mult Scler. 2005; 11(4): 398–402.
    CrossRefPubMed
  88. Truini A, Barbanti P, Pozzilli C, et al. A mechanism-based classification of pain in multiple sclerosis. J Neurol. 2013; 260(2): 351–367.
    CrossRefPubMed
  89. Miller L, Mattison P, Paul L, et al. The effects of transcutaneous electrical nerve stimulation (TENS) on spasticity in multiple sclerosis. Mult Scler. 2007; 13(4): 527–533.
    CrossRefPubMed
  90. Brola W, Mitosek-Szewczyk K, Opara J. Symptomatology and pathogenesis of different types of pain in multiple sclerosis. Neurol Neurochir Pol. 2014; 48(4): 272–279.
    CrossRefPubMed
  91. D'Amico D, La Mantia L, Rigamonti A, et al. Prevalence of primary headaches in people with multiple sclerosis. Cephalalgia. 2004; 24(11): 980–984.
    CrossRefPubMed
  92. Putzki N, Pfriem A, Limmroth V, et al. Prevalence of migraine, tension-type headache and trigeminal neuralgia in multiple sclerosis. Eur J Neurol. 2009; 16(2): 262–267.
    CrossRefPubMed
  93. Beck RW, Gal RL. Treatment of acute optic neuritis: a summary of findings from the optic neuritis treatment trial. Arch Ophthalmol. 2008; 126(7): 994–995.
    CrossRefPubMed
  94. Wissel J, Müller J, Dressnandt J, et al. Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage. 2000; 20(1): 44–49.
    CrossRefPubMed
  95. Zajicek JP, Apostu VI. Role of cannabinoids in multiple sclerosis. CNS Drugs. 2011; 25(3): 187–201.
    CrossRefPubMed
  96. Modestowicz R, Sosnowski P, Wender M, et al. Morfologia ognisk demielinizacyjnych a zaburzenia funkcji poznawczych i emocjonalnych u chorych na stwardnienie rozsiane. Neurol Neurochir Pol. 2000; 34: 23–34.
  97. Zakrzewska-Pniewska B. Zaburzenia funkcji poznawczych w stwardnieniu rozsianym. In: Szczudlik A, Liberski PP, Barcikowska M. ed. Otępienie. Wydawnictwo UJ, Kraków 2004.
  98. Kurkowska-Jastrzębska I, Mirowska-Guzel D. Zaburzenia poznawcze w stwardnieniu rozsianym i możliwości terapii. Pol Przeg Neurol. 2008; 4(Suppl A): 52–53.
  99. Julian LJ, Julian LJ, Arnett PA, et al. Cognitive predictors of response to treatment for depression in multiple sclerosis. J Neuropsychiatry Clin Neurosci. 2006; 18(3): 356–363.
    CrossRefPubMed
  100. Kalb R, Beier M, Benedict RHb, et al. Recommendations for cognitive screening and management in multiple sclerosis care. Mult Scler. 2018; 24(13): 1665–1680.
    CrossRefPubMed
  101. Huijbregts SCJ, Kalkers NF, de Sonneville LMJ, et al. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS. Neurology. 2004; 63(2): 335–339.
    CrossRefPubMed
  102. Amato MP, Zipoli V, Portaccio E. Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies. J Neurol Sci. 2006; 245(1-2): 41–46.
    CrossRefPubMed
  103. Gaudino EA, Chiaravalloti ND, DeLuca J, et al. A comparison of memory performance in relapsing-remitting, primary progressive and secondary progressive, multiple sclerosis. Neuropsychiatry Neuropsychol Behav Neurol. 2001; 14(1): 32–44.
    PubMed
  104. Smestad C, Sandvik L, Landrø NI, et al. Cognitive impairment after three decades of multiple sclerosis. Eur J Neurol. 2010; 17(3): 499–505.
    CrossRefPubMed
  105. Polman CH, Rudick RA. The multiple sclerosis functional composite: a clinically meaningful measure of disability. Neurology. 2010; 74(Suppl 3): S8–15.
    CrossRefPubMed
  106. Bakirtzis C, Ioannidis P, Messinis L, et al. The rationale for monitoring cognitive function in multiple sclerosis: practical issues for clinicians. Open Neurol J. 2018; 12(1): 31–40.
    CrossRefPubMed
  107. Filippi M. Cortical reorganisation in patients with MS. J Neurol Neurosurg Psychiatry. 2004; 75(8): 1087–1089.
    CrossRefPubMed
  108. Wishart HA, Saykin AJ, McDonald BC, et al. Brain activation patterns associated with working memory in relapsing-remitting MS. Neurology. 2004; 62(2): 234–238.
    CrossRefPubMed
  109. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 2008; 7(12): 1139–1151.
    CrossRefPubMed
  110. Sumowski JF, Benedict R, Enzinger C, et al. Cognition in multiple sclerosis: state of the field and priorities for the future. Neurology. 2018; 90(6): 278–288.
    CrossRefPubMed
  111. Weinstein A, Schwid SR, Schiffer RB, et al. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol. 1999; 56(3): 319–324.
    CrossRefPubMed
  112. Kappos L, Freedman M, Polman C, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 2009; 8(11): 987–997.
    CrossRef
  113. Mattioli F, Stampatori C, Bellomi F, et al. Natalizumab efficacy on cognitive impairment in MS. Neurol Sci. 2011; 31(Suppl 3): 321–323.
    CrossRefPubMed
  114. Marrie RA, Reingold S, Cohen J, et al. A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis. Mult Scler. 2015; 21(3): 342–349.
    CrossRefPubMed
  115. Minden SL, Feinstein A, Kalb RC, et al. Guideline Development Subcommittee of the American Academy of Neurology. Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014; 82(2): 174–181.
    CrossRefPubMed
  116. Rybakowski J, Pużyński S, Wciórka J. Psychiatria. Vol 2. Elsevier Urban & Partner, Wrocław 2010: 305–375.
  117. Feinstein A, Pavisian B. Multiple sclerosis and suicide. Mult Scler. 2017; 23(7): 923–927.
    CrossRefPubMed
  118. Brola W, Fudala M, Czernicki J. Wpływ depresji na jakość życia chorych ze stwardnieniem rozsianym. Rehabil Med. 2007; 11: 9–13.
  119. Pérez LP, González RS, Lázaro EB. Treatment of mood disorders in multiple sclerosis. Curr Treat Options Neurol. 2015; 17(1): 323.
    CrossRefPubMed
  120. Turner AP, Alschuler KN, Hughes AJ, et al. Mental Health Comorbidity in MS: Depression, Anxiety, and Bipolar Disorder. Curr Neurol Neurosci Rep. 2016; 16(12): 106.
    CrossRefPubMed
  121. Marrie RA, Patten SB, Tremlett H, et al. CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis. Sex differences in comorbidity at diagnosis of multiple sclerosis: a population-based study. Neurology. 2016; 86(14): 1279–1286.
    CrossRefPubMed
  122. Korostil M, Feinstein A. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult Scler. 2007; 13(1): 67–72.
    CrossRefPubMed

Informacje o plikach cookie

Niezbędne pliki cookie

Zawsze aktywne

Te pliki cookie są niezbędne do prawidłowego wyświetlania i działania strony internetowej. Zablokowanie ich może spowodować nieprawidłowe działanie strony.

Analityczne pliki cookie

W ramach naszej strony internetowej korzystamy z narzędzi analitycznych, takich jak Google Analytics, które umożliwiają nam weryfikację ruchu na stronie internetowej. Narzędzia te mogą wymagać użycia plików cookie.

Społecznościowe pliki cookie

Są to pliki cookie powiązane z portalami społecznościowymi, z których korzystamy. Zaakceptowanie ich pozwoli na powiązanie Twojej wizyty na stronie z naszymi profilami w mediach społecznościowych.

Marketingowe pliki cookie

Są to pliki cookie odpowiedzialne za prowadzenie działań reklamowych i marketingowych - zgoda na ich wykorzystanie pozwoli nam kierować do Ciebie reklamy, bazujące na podstawie Twoich wcześniejszych aktywności w ramach naszej stronie internetowej.

Copyright © 2023-2024 Via Medica Regulamin Polityka cookies Polityka prywatności Nota prawna